Tango Therapeutics, Inc. announced that the first patient has been dosed in its TNG456 Phase 1/2 trial. This trial focuses on patients with MTAP-deleted solid tumors, with a particular emphasis on glioblastoma (GBM), a highly aggressive and difficult-to-treat brain cancer. TNG456 is designed as a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor, aiming to address a critical need in CNS oncology.
Glioblastoma presents a significant challenge in oncology, with a five-year survival rate below 10% and limited treatment options. Approximately 45% of GBM cases are MTAP-deleted, indicating a substantial patient population that could potentially benefit from TNG456. Preclinical studies for TNG456 demonstrated favorable potency, MTAP-selectivity, and brain exposure, suggesting its potential for meaningful efficacy in GBM.
The Phase 1/2 clinical trial (NCT06810544) is evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of TNG456 as a monotherapy and in combination with abemaciclib. The initial dose escalation phase is currently enrolling patients with TNG456 monotherapy, specifically focusing on glioblastoma patients.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.